Caliway Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to treat Dercum's Disease

/PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the United States Food and Drug Administration (U.S. FDA) has accepted the CBL-514...

Related Keywords

United States ,Taiwan ,Bax Bcl ,Drug Administration ,Global Dercum Disease Market Research ,United States Food ,New Drug ,Global Dercum ,Disease Market Research Report ,Caliway Biopharmaceuticals ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Fda Approval ,Clinical Trials Amp Medical Discoveries ,